Brief: Ondine Biomedical Commences US Phase 3 Clinical Trial
17/12/2024 07:47
Dec 17 (Reuters) - Ondine Biomedical Inc OBI.L :
* ONDINE COMMENCING US PHASE 3 CLINICAL TRIAL
* EARLY RESULTS OF ONDINE'S PHASE 3 TRIAL EXPECTED IN AUTUMN
2025
Source text: ID:nRSQ3059Qa
Further company coverage: OBI.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ondine Biomedical
See all newsBrief: Ondine Lantern Phase 3 Database Lock Expected Within A Week; Top-Line Results In 1-2 Weeks
Ondine Biomedical - Leeds Drops SSIs by 78.5% in Complex Brain Surgery
Brief: Ondine Biomedical Expects 2026 To Be A Defining Year For Company
Ondine Biomedical - Notice of AGM
Ondine Biomedical - 2025 Full Year Results and Annual Report